Recognizing Dementia
To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.
Starts On:
7/19/2023: 12:00 AM
Ends On:
7/19/2025: 12:00 AM
Session Type:
Internet Activity Enduring Material
Credits:
1
Description:
Planning Committee:
Allyson Zazulia, MD, Course Chair
Professor of Neurology and Radiology
Associate Dean for Continuing Medical Education
Disclosures: None
Kyle Womack, MD, Course Co-Chair
Professor, Neurology Division of Adult Neurology
Disclosures: None
Abbey Arnold, MSN
Nurse Practitioner, Knight ADRC
Disclosures: None
Tanya Harte, NP
Family Nurse Practitioner, Barnes-Jewish Hospital
Disclosures: None
Madeline Marie Paczynski, PA, MCMSc
Neurology Physician Assistant, Washington University
Disclosures: None
Nicole Elmore, NP
Adult Care Nurse Practitioner
Disclosures: None
Planning Committee:
Allyson Zazulia, MD, Course Chair
Professor of Neurology and Radiology
Associate Dean for Continuing Medical Education
Disclosures: None
Kyle Womack, MD, Course Co-Chair
Professor, Neurology Division of Adult Neurology
Disclosures: None
Abbey Arnold, MSN
Nurse Practitioner, Knight ADRC
Disclosures: None
Tanya Harte, NP
Family Nurse Practitioner, Barnes-Jewish Hospital
Disclosures: None
Madeline Marie Paczynski, PA, MCMSc
Neurology Physician Assistant, Washington University
Disclosures: None
Nicole Elmore, NP
Adult Care Nurse Practitioner
Disclosures: None
Objectives:
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Recognize cognitive impairment in adults
- Use effective communication strategies with cognitively impaired adults
- Assess adults for cognitive impairment and diagnose dementia using guideline-based tools
- Provide appropriate management and care planning for adults with dementia
Additional Information:
Target Audience: This course is designed for physicians, nurses, nurse practitioners and pharmacists who specialize in neurology, internal medicine, family & general practice, and hospital medicine. The intended goal of this activity is increased knowledge, competence and performance and enhanced patient care.
Publication Date: July 19, 2023
Expiration Date: July 19, 2025
Publication Date: July 19, 2023
Expiration Date: July 19, 2025
Accreditation Information:
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Statement:
Credit Awarded for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 1 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credits for learning and change.
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 1 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credits for learning and change.
References:
Abbott A. (2023). Conquering Alzheimer's: a look at the therapies of the future. Nature, 616(7955), 26–28. https://doi.org/10.1038/d41586-023-00954-w
Administration on Aging. Eldercare locator. https://eldercare.acl.gov/Public/index.aspx
Alzheimer Association. (2021). 2021 Alzheimer's Disease Facts and Figures. Alzheimer Dementia, 17(3) doi:10.1212/CON.0000000000001133
Alzheimer's Association. Home. Alzheimer's Disease and Dementia. www.alz.org
American Geriatrics Society. (2019). American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of American Geriatric Society, 67, 674-694. doi: 10.1111/jgs.15767
Armstrong M. J. (2019). Lewy Body Dementias. Continuum (Minneapolis, Minn.), 25(1), 128–146. https://doi.org/10.1212/CON.0000000000000685
Bennett, S. & Thomas, A. J. (2014). Depression and dementia: Cause, consequence, or coincidence? Maturitas, 79, 184-190. doi: 10.1016/j.maturitas.2014.05.009.
C₂N Diagnostics. PrecivityAD®. https://precivityad.com/
Carlsson, C.M. (2022). Management of Dementia. Continuum, 28(3), 885-900. doi: 10.1212/CON.0000000000001132.
Centers for Medicare & Medicaid Services. (2023, January 6). CMS statement on FDA accelerated approval of Lecanemab. https://www.cms.gov/newsroom/press-releases/cms-statement-fda-accelerated-approval-lecanemab#:~:text=As%20announced%20in%20April%202022,CMS's%20existing%20national%20coverage%20determination.
Centers for Medicare & Medicaid Services. (2023, May 5). NCA – monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease (CAG-00450N) – decision memo. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305
Chang Wong, E., & Chang Chui, H. (2022). Vascular Cognitive Impairment and Dementia. Continuum (Minneapolis, Minn.), 28(3), 750–780. https://doi.org/10.1212/CON.0000000000001124
Chapleau, M., Iaccarino, L., Soleimani-Meigooni, D., & Rabinovici, G.D. (2022). The role of amyloid PET in imaging neurodegenerative disorders: A review. Journal of Nuclear Medicine, 63(Suppl 1), 13S-19S. doi:10.2967/jnumed.121.263195
Chodosh, J., Petitti, D. B., Elliott, M., Hays, R. D., Crooks, V. C., Reuben, D. B., Buckwalter, G., & Wenger, N. (2004). Physician recognition of cognitive impairment: Evaluating the need for improvement. Journal of the American Geriatrics Society, 52, 1051-1059.
Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021). Aducanumab: Appropriate Use Recommendations. The journal of prevention of Alzheimer's disease, 8(4), 398–410. https://doi.org/10.14283/jpad.2021.41
Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022). Alzheimer's disease drug development pipeline: 2022. Alzheimer's & dementia (New York, N. Y.), 8(1), e12295. https://doi.org/10.1002/trc2.12295
Day G.S. (2022). Rapidly Progressive Dementia. Continuum, 28(3), 901-936. doi:10.1212/CON.0000000000001089
Eisenmann, Y., Golla, H., Schmidt, H., Voltz, R., & Perrar, K. M. (2020). Palliative Care in Advanced Dementia. Frontiers in psychiatry, 11, 699. https://doi.org/10.3389/fpsyt.2020.00699
Finger E. C. (2016). Frontotemporal Dementias. Continuum (Minneapolis, Minn.), 22(2 Dementia), 464–489. https://doi.org/10.1212/CON.0000000000000300
Fong, T. G., & Inouye, S. K. (2022). The inter-relationship between delirium and dementia: the importance of delirium prevention. Nature reviews. Neurology, 18(10), 579–596. https://doi.org/10.1038/s41582-022-00698-7
Healthy People 2030, U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. Retrieved April 23, 2023, from https://health.gov/healthypeople/objectives-and-data/social-determinants-health
Iwasaki, Y., Mori, K., Ito, M., et al. (2021). System degeneration in an MM1-type sporadic Creutzfeldt-Jakob disease case with an unusually prolonged akinetic mutism state. Prion, 15(1), 12-20. doi:10.1080/19336896.2020.1868931
Jack, C. R., Jr, Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet. Neurology, 9(1), 119–128. https://doi.org/10.1016/S1474-4422(09)70299-6
Knight Alzheimer Disease Research Center. AD8® dementia screening interview. https://knightadrc.wustl.edu/professionals-clinicians/ad8-instrument/
Kornblith E., Bahorik A., Boscardin W.J., Xia F., Barnes D.E., Yaffe K. (2022). Association of Race and Ethnicity With Incidence of Dementia Among Older Adults. JAMA, 327(15). 1488–1495. doi:10.1001/jama.2022.3550
McDade E. M. (2022). Alzheimer Disease. Continuum (Minneapolis, Minn.), 28(3), 648–675. https://doi.org/10.1212/CON.000000000000113
Administration on Aging. Eldercare locator. https://eldercare.acl.gov/Public/index.aspx
Alzheimer Association. (2021). 2021 Alzheimer's Disease Facts and Figures. Alzheimer Dementia, 17(3) doi:10.1212/CON.0000000000001133
Alzheimer's Association. Home. Alzheimer's Disease and Dementia. www.alz.org
American Geriatrics Society. (2019). American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of American Geriatric Society, 67, 674-694. doi: 10.1111/jgs.15767
Armstrong M. J. (2019). Lewy Body Dementias. Continuum (Minneapolis, Minn.), 25(1), 128–146. https://doi.org/10.1212/CON.0000000000000685
Bennett, S. & Thomas, A. J. (2014). Depression and dementia: Cause, consequence, or coincidence? Maturitas, 79, 184-190. doi: 10.1016/j.maturitas.2014.05.009.
C₂N Diagnostics. PrecivityAD®. https://precivityad.com/
Carlsson, C.M. (2022). Management of Dementia. Continuum, 28(3), 885-900. doi: 10.1212/CON.0000000000001132.
Centers for Medicare & Medicaid Services. (2023, January 6). CMS statement on FDA accelerated approval of Lecanemab. https://www.cms.gov/newsroom/press-releases/cms-statement-fda-accelerated-approval-lecanemab#:~:text=As%20announced%20in%20April%202022,CMS's%20existing%20national%20coverage%20determination.
Centers for Medicare & Medicaid Services. (2023, May 5). NCA – monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease (CAG-00450N) – decision memo. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305
Chang Wong, E., & Chang Chui, H. (2022). Vascular Cognitive Impairment and Dementia. Continuum (Minneapolis, Minn.), 28(3), 750–780. https://doi.org/10.1212/CON.0000000000001124
Chapleau, M., Iaccarino, L., Soleimani-Meigooni, D., & Rabinovici, G.D. (2022). The role of amyloid PET in imaging neurodegenerative disorders: A review. Journal of Nuclear Medicine, 63(Suppl 1), 13S-19S. doi:10.2967/jnumed.121.263195
Chodosh, J., Petitti, D. B., Elliott, M., Hays, R. D., Crooks, V. C., Reuben, D. B., Buckwalter, G., & Wenger, N. (2004). Physician recognition of cognitive impairment: Evaluating the need for improvement. Journal of the American Geriatrics Society, 52, 1051-1059.
Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021). Aducanumab: Appropriate Use Recommendations. The journal of prevention of Alzheimer's disease, 8(4), 398–410. https://doi.org/10.14283/jpad.2021.41
Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022). Alzheimer's disease drug development pipeline: 2022. Alzheimer's & dementia (New York, N. Y.), 8(1), e12295. https://doi.org/10.1002/trc2.12295
Day G.S. (2022). Rapidly Progressive Dementia. Continuum, 28(3), 901-936. doi:10.1212/CON.0000000000001089
Eisenmann, Y., Golla, H., Schmidt, H., Voltz, R., & Perrar, K. M. (2020). Palliative Care in Advanced Dementia. Frontiers in psychiatry, 11, 699. https://doi.org/10.3389/fpsyt.2020.00699
Finger E. C. (2016). Frontotemporal Dementias. Continuum (Minneapolis, Minn.), 22(2 Dementia), 464–489. https://doi.org/10.1212/CON.0000000000000300
Fong, T. G., & Inouye, S. K. (2022). The inter-relationship between delirium and dementia: the importance of delirium prevention. Nature reviews. Neurology, 18(10), 579–596. https://doi.org/10.1038/s41582-022-00698-7
Healthy People 2030, U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. Retrieved April 23, 2023, from https://health.gov/healthypeople/objectives-and-data/social-determinants-health
Iwasaki, Y., Mori, K., Ito, M., et al. (2021). System degeneration in an MM1-type sporadic Creutzfeldt-Jakob disease case with an unusually prolonged akinetic mutism state. Prion, 15(1), 12-20. doi:10.1080/19336896.2020.1868931
Jack, C. R., Jr, Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet. Neurology, 9(1), 119–128. https://doi.org/10.1016/S1474-4422(09)70299-6
Knight Alzheimer Disease Research Center. AD8® dementia screening interview. https://knightadrc.wustl.edu/professionals-clinicians/ad8-instrument/
Kornblith E., Bahorik A., Boscardin W.J., Xia F., Barnes D.E., Yaffe K. (2022). Association of Race and Ethnicity With Incidence of Dementia Among Older Adults. JAMA, 327(15). 1488–1495. doi:10.1001/jama.2022.3550
McDade E. M. (2022). Alzheimer Disease. Continuum (Minneapolis, Minn.), 28(3), 648–675. https://doi.org/10.1212/CON.000000000000113
Disclosure Information:
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
This course is intended for healthcare professionals only. Continuing Medical Education at Washington University School of Medicine fully complies with the legal requirements of the Americans with Disabilities Act rules and regulations thereof. If any participant of this course is in need of accommodations, please contact us at cme@wustl.edu.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
Category:
Medicine, Neurology
Accreditation
AMA: 1.00
ANCC: 1.00
Attendance: 1.00
IPCE: 1.00
